Literature DB >> 23013528

Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease.

W C Sun1, Y C Sun, H Lin, B Yan, G X Shi.   

Abstract

BACKGROUND: It has been speculated that viral infection might be one of the potential aetiologies for adult-onset clinically amyopathic dermatomyositis (CADM). The molecular pathogenesis remains largely unknown.
OBJECTIVES: To explore whether dysregulation of the type I interferon (IFN) system is involved in the pathogenesis of CADM.
METHODS: We studied 16 patients with CADM and compared them with healthy control subjects (n = 20) and patients with classic dermatomyositis (DM, n = 16) and polymyositis (PM, n = 16). Expressions of mRNA for serial toll-like receptor genes (TLR2, TLR3, TLR4, TLR7, TLR8 and TLR9) and type I IFN-regulated genes (IRF7, ISG15 and MxA) in peripheral blood leucocytes (PBL) were detected by real-time polymerase chain reaction analysis. The level of IFN-α in blood was tested by enzyme-linked immunosorbent assay.
RESULTS: The mRNA expressions of TLR7, TLR9 and IRF7 were greatly elevated in the PBL from patients with CADM compared with controls. Upregulation of the ISG15 and MxA genes was detected in the PBL from patients with CADM, as well as from patients with classic DM. Among the four study groups, the overproduction of IFN-α in blood was most significant in the CADM group. Especially, IFN-α level was obviously high in the clinical interstitial lung disease (ILD) subgroup of patients with CADM. Positive correlations were found between IFN-α concentration and other unfavourable prognostic factors of CADM-associated ILD.
CONCLUSIONS: Our data suggest that the dysregulation of the type I IFN system may be implicated in CADM pathogenesis. IFN-α may be a useful biomarker for assessing the disease severity of CADM-associated ILD.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23013528     DOI: 10.1111/j.1365-2133.2012.11145.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

Review 1.  MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2017-04

2.  ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.

Authors:  Airi Nishimi; Takeo Isozaki; Shinichiro Nishimi; Sho Ishii; Takahiro Tokunaga; Hidekazu Furuya; Kuninobu Wakabayashi; Tsuyoshi Kasama
Journal:  Clin Rheumatol       Date:  2018-02-06       Impact factor: 2.980

3.  Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis.

Authors:  Atsushi Tanaka; Hiroshi Tsukamoto; Hiroki Mitoma; Chikako Kiyohara; Naoyasu Ueda; Masahiro Ayano; Shun-ichiro Ohta; Yasutaka Kimoto; Mitsuteru Akahoshi; Yojiro Arinobu; Hiroaki Niiro; Yoshifumi Tada; Takahiko Horiuchi; Koichi Akashi
Journal:  Arthritis Res Ther       Date:  2015-02-10       Impact factor: 5.156

4.  Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling.

Authors:  Alain Meyer; Ghada Alsaleh; Claude Heuschling; Jacques-Eric Gottenberg; Philippe Georgel; Benard Geny; Seiamak Bahram; Jean Sibilia
Journal:  RMD Open       Date:  2016-10-31

5.  Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study.

Authors:  Katsuhiro Oda; Takuya Kotani; Tohru Takeuchi; Takaaki Ishida; Takeshi Shoda; Kentaro Isoda; Shuzo Yoshida; Yasuichiro Nishimura; Shigeki Makino
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

Review 6.  Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.

Authors:  Pankti Mehta; Pedro M Machado; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-03-27       Impact factor: 2.631

7.  Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis.

Authors:  Wenli Li; Chuiwen Deng; Hanbo Yang; Xin Lu; Shanshan Li; Xia Liu; Fang Chen; Lida Chen; Xiaoming Shu; Lu Zhang; Qingyan Liu; Guochun Wang; Qinglin Peng
Journal:  Arthritis Res Ther       Date:  2021-01-07       Impact factor: 5.156

8.  Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department.

Authors:  Keyun Tang; Hanlin Zhang; Hongzhong Jin
Journal:  Front Med (Lausanne)       Date:  2021-12-02

9.  Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.

Authors:  Dong Jin Go; Eun Young Lee; Eun Bong Lee; Yeong Wook Song; Maximilian Ferdinand Konig; Jin Kyun Park
Journal:  J Korean Med Sci       Date:  2016-02-04       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.